The study, which was funded through a $5.7 million NIH grant disbursed in 2015, paid scientists to administer puberty blockers to two cohorts of children.
Ultra-low fees kept monetization in the basis-point range, leaving revenue unable to offset steep losses despite surging Hong Kong trading volumes.
...